Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stakeholders discuss biosimilar naming, substitution.

× No keyword cloud information.

4 in total

Review 1. Regulatory and clinical considerations for biosimilar oncology drugs.

Authors: Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal: Lancet Oncol Date: 2014-11-24 Impact factor: 41.316

Review 2. A Framework for Integrating Biosimilars Into the Didactic Core Requirements of a Doctor of Pharmacy Curriculum.

Authors: Edward Li; Jennifer Liu; Monica Ramchandani
Journal: Am J Pharm Educ Date: 2017-04 Impact factor: 2.047

Review 3. Regulatory considerations in oncologic biosimilar drug development.

Authors: Judith C Macdonald; Helen Hartman; Ira A Jacobs
Journal: MAbs Date: 2015 Impact factor: 5.857

Review 4. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.

Authors: Eduardo Mysler; Carlos Pineda; Takahiko Horiuchi; Ena Singh; Ehab Mahgoub; Javier Coindreau; Ira Jacobs
Journal: Rheumatol Int Date: 2016-02-27 Impact factor: 2.631

4 in total